ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
레녹스-가스토 증후군 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 예측 기간 동안의 성장은 뇌 이상 및 신경 장애의 발생률 증가, 레녹스-가스토 증후군(LGS)을 포함한 전 세계적으로 간질 유병률 증가, 희귀 신경 질환에 대한 인식 제고, 간질 및 LGS 연구에 대한 자금 및 투자 증가, 최근 임상 시험 및 연구에서 얻은 고무적인 결과 등에 기인할 수 있습니다. 이 기간 동안 예상되는 주요 동향으로는 혁신적인 항발작 치료법 개발, 맞춤형 치료 접근법을 위한 정밀 의학의 발전, 신약의 규제 승인, LGS 진단 기술의 발전, 제약 회사와 연구 기관 간의 협력 강화 등이 있습니다.
뇌 이상 발생률의 증가는 향후 몇 년 동안 레녹스-가스토 증후군(LGS) 시장의 성장을 촉진할 것으로 예상됩니다. 뇌 이상은 일반적인 발달이나 기능과 다른 뇌의 구조적 또는 기능적 이상을 의미합니다. 이러한 이상 증상의 증가는 주로 대기 오염 물질 및 산업용 화학 물질을 비롯한 환경 독소에 대한 노출이 증가함에 따라, 특히 유아기에 뇌 발달 및 신경 기능을 방해하기 때문으로 보입니다. LGS는 치료하지 않고 방치할 경우 발달 지연, 인지 장애, 장기적인 신경학적 손상을 초래할 수 있는 중증의 의약품 내성 발작과 관련이 있기 때문에 이러한 이상을 관리하기 위해서는 LGS 치료가 필수적입니다. 예를 들어(2024년) 5월 미국 질병통제예방센터(CDC)는 2021년부터 2022년까지 미국에서 약 290만 명의 성인이 활동성 간질을 앓고 있으며, 이는 성인 인구의 약 1%를 차지한다고 보고했습니다. 따라서 뇌 이상 발생률의 증가는 LGS 시장 확대에 크게 기여할 것으로 예상됩니다./p>
LGS 시장의 주요 기업들은 치료 결과를 개선하고 맞춤형 치료를 제공하기 위해 정밀 의학 등 첨단 솔루션의 개발을 우선 과제로 삼고 있습니다. 정밀 의학은 개인의 유전적 구성, 환경적 요인 및 생활 습관을 바탕으로 예방, 진단 및 치료 전략을 수립하는 맞춤형 의료 접근법입니다. 예를 들어, 2022년 3월, 벨기에에 본사를 둔 바이오 제약 회사인 UCB는 2세 이상의 LGS 환자의 발작을 치료하기 위한 FINTEPLA 경구 용액에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 이 승인은 263명의 참가자를 대상으로 한 전 세계 3상 무작위 위약 대조 임상 시험 결과에서 발작 빈도가 현저히 감소한 것으로 입증되어 뒷받침되었습니다. FINTEPLA는 의약품에 내성이 있는 발작과 심각한 건강 합병증이 특징인 희귀하고 심각한 소아기 발병 간질인 LGS를 관리하기 위한 새로운 치료 옵션을 제공합니다. LGS는 미국에서 약 30,000-50,000명이 앓고 있는 것으로 추정됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 레녹스-가스토 증후군 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 레녹스-가스토 증후군 시장 : 성장률 분석
세계 레녹스-가스토 증후군 시장 실적 : 규모와 성장(2019-2024년)
세계의 레녹스-가스토 증후군 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 레녹스-가스토 증후군 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 레녹스-가스토 증후군 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항간질제
미주 신경 자극
케톤 생성 식단
칸나비디올
칸나비노이드
세계의 레녹스-가스토 증후군 시장 : 간질 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
탈력 발작
미오크로니 발작
강직 발작
비정형 결신 발작
기타
세계의 레녹스-가스토 증후군 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아
성인
고령자
세계의 레녹스-가스토 증후군 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
비경구
세계의 레녹스-가스토 증후군 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
기타
세계의 레녹스-가스토 증후군 시장 : 항간질제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
발프로산
라모트리긴
토피라마트
루피나미드
크로바잠
펠바메이트
레베티라세탐
기타
세계의 레녹스-가스토 증후군 시장 : 미주 신경 자극 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
이식형 미주 신경 자극 장치
외부 미주 신경 자극 장치
세계의 레녹스-가스토 증후군 시장 : 케톤 생성 식단 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
클래식 케톤 생성 식단
수정 앳킨스 식단
중쇄 지방산 트리글리세리드(MCT) 식단
저글리세믹 지수 치료
세계의 레녹스-가스토 증후군 시장 : 칸나비디올 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
에피디오렉스(FDA 승인)
기타 배합 칸나비디올 제품
세계의 레녹스-가스토 증후군 시장 : 칸나비노이드 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
THC 기반 제품
합성 칸나비노이드
THC 또는 CBD 배합 제형
제7장 지역 및 국가별 분석
세계의 레녹스-가스토 증후군 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 레녹스-가스토 증후군 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
레녹스-가스토 증후군 시장 : 경쟁 구도
레녹스-가스토 증후군 시장 : 기업 프로파일
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
UCB Pharma SA
Eisai Co. Ltd.
제31장 기타 주요 기업 및 혁신 기업
Jazz Pharmaceuticals plc
H. Lundbeck A/S
LivaNova PLC
Supernus Pharmaceuticals Inc.
Harmony Biosciences Holdings Inc.
Upsher-Smith Laboratories LLC
Catalyst Pharmaceuticals Inc.
SK Life Science Inc.
Esteive Therapeutics Inc.
NeuroPace Inc.
Marinus Pharmaceuticals Inc.
Stoke Therapeutics Inc.
Xenon Pharmaceuticals Inc.
Insys Therapeutics Inc.
Ovid Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
레녹스-가스토 증후군 시장(2029년) : 새로운 기회를 제공하는 국가
레녹스-가스토 증후군 시장(2029년) : 새로운 기회를 제공하는 부문
레녹스-가스토 증후군 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Lennox-Gastaut syndrome is a severe neurological disorder that typically begins in early childhood, characterized by multiple types of seizures, cognitive impairments, and distinctive electroencephalogram (EEG) patterns. This condition significantly affects developmental progress, resulting in challenges with motor skills, speech, and intellectual functioning.
Primary treatment options for Lennox-Gastaut syndrome include antiepileptic drugs, vagus nerve stimulation, the ketogenic diet, cannabidiol, and other cannabinoids. Antiepileptic drugs are used to prevent or lessen the frequency and intensity of seizures. They are effective in managing various seizure types such as atonic, myoclonic, tonic, and atypical absence seizures, and are used across pediatric, adult, and geriatric populations. These medications can be administered via oral or parenteral routes and are dispensed through various healthcare settings, including hospitals, specialty clinics, and others.
The lennox-gastaut syndrome market research report is one of a series of new reports from The Business Research Company that provides lennox-gastaut syndrome market statistics, including lennox-gastaut syndrome industry global market size, regional shares, competitors with a lennox-gastaut syndrome market share, detailed lennox-gastaut syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the lennox-gastaut syndrome industry. This lennox-gastaut syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The lennox gastaut syndrome market size has grown strongly in recent years. It will grow from $0.69 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. Growth during the historic period can be attributed to an expanding patient population driven by improved diagnostic techniques, increased government initiatives and support for epilepsy awareness, advancements in pediatric epilepsy management, rising demand for treatments with fewer side effects, and enhanced healthcare infrastructure and access to care.
The lennox gastaut syndrome market size is expected to see strong growth in the next few years. It will grow to $0.97 billion in 2029 at a compound annual growth rate (CAGR) of 7%. Growth in the forecast period can be attributed to the rising incidence of brain abnormalities and neurological disorders, the increasing global prevalence of epilepsy, including Lennox-Gastaut Syndrome (LGS), greater awareness of rare neurological conditions, increased funding and investment in epilepsy and LGS research, and encouraging results from recent clinical trials and studies. Key trends expected during this period include the development of innovative anti-seizure therapies, progress in precision medicine for personalized treatment approaches, regulatory approval of new drugs, technological advancements in LGS diagnostics, and strengthened collaboration between pharmaceutical companies and research institutions.
The rising incidence of brain abnormalities is expected to drive the growth of the Lennox-Gastaut Syndrome (LGS) market in the coming years. Brain abnormalities refer to structural or functional deviations in the brain that differ from typical development or function. The increase in such abnormalities is largely attributed to growing exposure to environmental toxins, including air pollutants and industrial chemicals, which can disrupt brain development and neurological functioning, especially during early childhood. Treatment for LGS is essential in managing these abnormalities, as the condition is associated with severe, drug-resistant seizures that can result in developmental delays, cognitive impairments, and long-term neurological damage if left untreated. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that approximately 2.9 million adults in the United States had active epilepsy during 2021 and 2022, accounting for about 1% of the adult population. Therefore, the growing incidence of brain abnormalities is expected to contribute significantly to the expansion of the LGS market.
Major companies in the Lennox-Gastaut Syndrome (LGS) market are prioritizing the development of advanced solutions, such as precision medicine, to improve treatment outcomes and provide personalized care. Precision medicine is a tailored medical approach that bases prevention, diagnosis, and treatment strategies on an individual's genetic makeup, environmental factors, and lifestyle. For example, in March 2022, UCB, a Belgium-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for FINTEPLA oral solution to treat seizures associated with LGS in patients aged two years and older. This approval was supported by results from a global Phase 3 randomized, placebo-controlled clinical trial with 263 participants, which demonstrated a significant reduction in drop seizure frequency. FINTEPLA offers a new therapeutic option for managing LGS, a rare and severe childhood-onset epilepsy characterized by drug-resistant seizures and serious health complications, affecting an estimated 30,000 to 50,000 people in the United States.
In March 2022, UCB, a pharmaceutical company based in Belgium, acquired Zogenix Inc. for $1.9 billion. Through this acquisition, UCB strengthened its position in the treatment of neurological disorders such as Lennox-Gastaut Syndrome (LGS) by adding Zogenix's advanced therapies, including FINTEPLA, to its portfolio. This strategic move aligns with UCB's commitment to addressing unmet medical needs in neurology. Zogenix Inc. is a U.S.-based company specializing in medications for Lennox-Gastaut Syndrome.
Major players in the lennox gastaut syndrome market are Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB Pharma S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, LivaNova PLC, Supernus Pharmaceuticals Inc., Harmony Biosciences Holdings Inc., Upsher-Smith Laboratories LLC, Catalyst Pharmaceuticals Inc., SK Life Science Inc., Aquestive Therapeutics Inc., NeuroPace Inc., Marinus Pharmaceuticals Inc., Stoke Therapeutics Inc., Xenon Pharmaceuticals Inc., Insys Therapeutics Inc., and Ovid Therapeutics Inc.
North America was the largest region in the lennox gastaut syndrome market in 2024. The regions covered in lennox gastaut syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lennox gastaut syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The lennox gastaut syndrome market consists of revenues earned by entities by providing services such as genetic and neurological diagnostic testing, seizure monitoring, neurodevelopmental assessments, and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The lennox gastaut syndrome market also includes sales of adaptive communication devices, protective helmets and safety gear, therapeutic toys, and feeding aids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lennox Gastaut Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lennox gastaut syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for lennox gastaut syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lennox gastaut syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Lennox Gastaut Syndrome Market Characteristics
3. Lennox Gastaut Syndrome Market Trends And Strategies
4. Lennox Gastaut Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Lennox Gastaut Syndrome Growth Analysis And Strategic Analysis Framework
5.1. Global Lennox Gastaut Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lennox Gastaut Syndrome Market Growth Rate Analysis
5.4. Global Lennox Gastaut Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lennox Gastaut Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lennox Gastaut Syndrome Total Addressable Market (TAM)
6. Lennox Gastaut Syndrome Market Segmentation
6.1. Global Lennox Gastaut Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiepileptic Drugs
Vagus Nerve Stimulation
Ketogenic Diet
Cannabidiol
Cannabinoids
6.2. Global Lennox Gastaut Syndrome Market, Segmentation By Epileptic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atonic Seizures
Myoclonic Seizures
Tonic Seizures
Atypical Absence Seizures
Other Types
6.3. Global Lennox Gastaut Syndrome Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.4. Global Lennox Gastaut Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.5. Global Lennox Gastaut Syndrome Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End Users
6.6. Global Lennox Gastaut Syndrome Market, Sub-Segmentation Of Antiepileptic Drugs,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Valproate
Lamotrigine
Topiramate
Rufinamide
Clobazam
Felbamate
Levetiracetam
Other Antiepileptic Drugs
6.7. Global Lennox Gastaut Syndrome Market, Sub-Segmentation Of Vagus Nerve Stimulation,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Implantable Vagus Nerve StimulationDevices
External Vagus Nerve StimulationDevices
6.8. Global Lennox Gastaut Syndrome Market, Sub-Segmentation Of Ketogenic Diet,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Classic Ketogenic Diet
Modified Atkins Diet
Medium Chain Triglyceride (MCT) Diet
Low Glycemic Index Treatment
6.9. Global Lennox Gastaut Syndrome Market, Sub-Segmentation Of Cannabidiol,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epidiolex (FDA Approved)
Other Prescription Cannabidiol Products
6.10. Global Lennox Gastaut Syndrome Market, Sub-Segmentation Of Cannabinoids,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
THC-based Products
Synthetic Cannabinoids
Combined THC Or CBD Formulations
7. Lennox Gastaut Syndrome Market Regional And Country Analysis
7.1. Global Lennox Gastaut Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lennox Gastaut Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
